11/27/21, 4:24 AM RePORT) RePORTER

Project Number

5R01AI110700-05

< Back to Search Results

Description

Details

Sub-Projects

Publications

Patents

Outcomes

Clinical Studies

News and More

(□) <u>History</u>

Similar Projects

Mechanisms of MERS-CoV Entry, Cross-species Transmission and Pathogenesis

Contact PI/Project Leader BARIC, RALPH S<u>Other Pls</u>

Awardee Organization
UNIV OF NORTH
CAROLINA CHAPEL HILL



Abstract Text

DESCRIPTION (provided by applicant): Recently, a novel and highly virulent Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV) emerged, causing ~40% mortality rates. MERS-CoV replicates efficiently in humans, camels and bats, but not mouse cells demonstrating a broad yet rodent-restricted host range. Ominously, person-to-person transmission and subclinical infections endanger global populations and economies. Importantly, we have demonstrated that closely related bat coronaviruses (Bt CoV), like HKU4, uses the same bat and human receptor for entry as MERS-CoV, raising the specter of further zoonotic introductions of antigenically distinct coronaviruses into human populations. Consequently, we develop a multidisciplinary program that includes X- Ray crystallography, electron microscopy, protein biochemistry, molecular virology, reverse genetics and animal model development to address fundamental questions regulating key BtCoV HKU4 and MERS-CoV-host structure-function relationships in: i) receptor mediated binding, fusion and entry, ii) cross species transmission, and iii) in vivo pathogenesis. MERS-CoV and BtCoV HKU4 encode an envelope-anchored spike glycoprotein (S) that binds to its host receptor dipeptidyl peptidase 4 (DPP4) through its S1 subunit, initiating a cascade of host serine protease regulated conformation changes that elicit S2-mediated membrane fusion and entry. The major barrier for HKU4 mediated entry into human cells occurs at protease initiated membrane fusion, rather than at the receptor binding interface. Thus, our program identifies a checkpoint associated with bat CoV cross species transmission into other mammals, including humans. In addition to identifying key structural and biochemical interactions that regulate S and DPP4 receptor ortholog-guided binding protease regulated fusion and entry, we apply reverse genetics, structure-guided mutations, and experimental evolution to study HKU4 and MERS-CoV host adaptation and pathogenesis, using recently developed transgenic animal models. In Aim 1, we study the biochemistry and structure of MERS-CoV and HKU4 bound to various species receptor-binding domains (RBD). In Aim 2, we study S processing by bat and human entry proteases. In Aim 3, we study HKU4 and MERS-CoV pathogenesis using transgenic mice and experimental evolution. The overall goal is to build a comprehensive understanding of the molecular mechanisms guiding group 2c CoV receptor recognition, entry and pathogenesis. In parallel, we produce key deliverables that are crucial for developing effective antivirals and vaccines, thereby improving rapid response and the overall global health.

Public Health Relevance Statement

PUBLIC HEALTH RELEVANCE: MERS-CoV is an emerging respiratory virus associated with ~40% mortality rates in humans. Virus receptor interactions and S glycoprotein-protease processing events are key regulators of entry, tissue tropism, species specificity and disease emergence. Our studies identify genetic pathways regulating CoV cross species transmission and receptor ortholog usage, resulting in robust animal models of human disease; critical reagents for therapeutic and vaccine testing.

NIH Spending Category

Biodefense Emerging Infectious Diseases Genetics Infectious Diseases

Project Terms

Address Animal Model Animals Antiviral Agents Binding

Binding Proteins Biochemical Biochemistry Biological Availability Camels

11/27/21, 4:24 AM RePORT) RePORTER

Back to Search Results

Description

Details

Sub-Projects

Publications

Patents

Outcomes

Clinical Studies

News and More

(L) History

Similar Projects

Mechanisms of MERS-CoV Entry, Cross-species Transmission and Pathogenesis

Project Number Contact PI/Project Leader Awardee Organization

5R01AI110700-05 BARIC, RALPH SOther PIs UNIV OF NORTH

CAROLINA CHAPEL HILL

Read More

Details

Contact PI/ Project

Leader

Name BARIC, RALPH S ☑

Title

PROFESSOR

Contact

RBARIC@EMAIL.UNC.EDU

Other PIs Program Official

Name Name

STEMMY, ERIK J

Contact

<u>erik.stemmy@nih.gov</u>

Organization

Name

UNIV OF NORTH CAROLINA

CHAPEL HILL

City

CHAPEL HILL

Country

UNITED STATES (US)

Department Type

PUBLIC HEALTH & PREV

MEDICINE

LI, FANG

Organization Type
SCHOOLS OF PUBLIC

HEALTH

State Code

NC

Congressional District

04

Other Information

FOA

PA-13-302

Study Section

Virology - A Study

Section[VIRA]

Award Notice

Date

Fiscal Year **13-March- 2019**

Administering Institutes or

Centers

NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS

DISEASES

DUNS Number CFDA Code **608195277 855**

Project Start

Date **2015**

Project End 24-

Date September-

2020

2020

01-April-

20-April-

Budget Start

Date **2019**

Budget End 24-

Date September-

2020

NIH Spending

Category

Project Funding Information for 2019

Total Funding Direct Costs Indirect Costs \$721,207 \$601,878 \$119,329

Year Funding IC

2019 NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES \$721,207

NIH Categorical Spending

Click here for more information on NIH Categorical Spending

Funding IC FY Total Cost by IC

Thank you for your feedback!

11/27/21, 4:24 AM RePORT) RePORTER

Project Number

5R01AI110700-05

Back to Search Results

Description

Details

Sub-Projects

Publications

'<u>Patents</u>

Outcomes

Clinical Studies

News and More

(L) History

Similar Projects

Mechanisms of MERS-CoV Entry, Cross-species Transmission and Pathogenesis

Contact PI/Project Leader BARIC, RALPH S<u>Other PIs</u>

Awardee Organization
UNIV OF NORTH
CAROLINA CHAPEL HILL

טוseases;



No Sub Projects information available for 5R01Al110700-05

Publications

No Publications available for 5R01Al110700-05

∀ Patents

No Patents information available for 5R01Al110700-05

Outcomes

The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.

No Outcomes available for 5R01Al110700-05

Clinical Studies

No Clinical Studies information available for 5R01Al110700-05

News and More

Related News Releases

No news release information available for 5R01Al110700-05

History

No Historical information available for 5R01Al110700-05

11/27/21, 4:24 AM RePORT > RePORTER

∢ Back to Search Results

Description

Details

Sub-Projects

Publications

Patents

Outcomes

Clinical Studies

News and More

<u>History</u>

Similar Projects

Mechanisms of MERS-CoV Entry, Cross-species Transmission and Pathogenesis

Project Number Contact PI/Project Leader 5R01AI110700-05 BARIC, RALPH SOther PIs

er Awardee Organization

Is UNIV OF NORTH

CAROLINA CHAPEL HILL